Leadership & Management
Novartis Country President ‘remains inspired’ by ANZ team as he prepares to depart for international role

Pharma News: Novartis has unveiled a significant organisational development. Richard Tew, Country President of Novartis Australia and New Zealand, will ascend to the role of Head, Customer and Market Activation within the International Commercial and Launch Strategy Division, heralding an exciting chapter in his career.
This transformative change is set to take effect on December 1st, and Mr Tew, along with his family, will embark on an inspiring journey to relocate to Basel, Switzerland. Notably, Mr Tew will maintain his position as Country President in Australia and New Zealand until a suitable successor is identified.
In reflecting on his illustrious tenure at the helm of Novartis in Australia and New Zealand, Mr Tew expressed his gratitude and enthusiasm for the future.
“It has been my privilege to have led Novartis across Australia and New Zealand over the past 5 years. Working with our team, patients, and customers to improve health outcomes across our innovative medicines’ portfolio has been the most rewarding experience of my career,” he expressed.
During his tenure, Mr Tew has played an instrumental role in expanding access to novel treatment options, particularly for infants diagnosed with Spinal Muscular Atrophy, a testament to Novartis’ unwavering commitment to advancing healthcare.
He further iterated, “I remain inspired by the energy, passion, and focus that our entire organisation brings to work every day as we strive to bring innovative treatments to patients across cardiovascular, oncology, immunology, and neuroscience therapeutic areas.”
Mr Tew’s tenure has witnessed the Novartis team’s resilience in navigating the complex external policy and access landscape, and he emphasized its significance.
He said “The resilience of the Novartis team continues to be a source of inspiration as we navigate a complex external policy and access environment. Every moment matters for patients across Australia and New Zealand, and I am confident that Novartis will continue to break new ground to reshape healthcare systems and accelerate access to medicines.”
His distinguished career has spanned over a decade at Novartis, during which he has held various leadership roles in the UK, Europe, and within the global organisation. He assumed the role of Country President, Australia and New Zealand in May 2021 and, prior to that, served as the Country Pharmaceutical Organisation Head.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Sussan Ley breaks ground as first female opposition leader amid Liberal party shake-up
Sussan Ley has made history as the country’s first female opposition leader, edging out former shadow treasurer Angus Taylor in […]
MoreNews & Trends - MedTech & Diagnostics

New procedure shows durable impact in type 2 diabetes
Medtech company, Endogenex, has unveiled promising data from an Australian clinical trial that could mark a turning point in type […]
MoreNews & Trends - Pharmaceuticals

AI rewrites the script on androgen deprivation therapy in prostate cancer
Artificial intelligence is showing promise in reshaping treatment decisions for men undergoing radiation therapy and androgen deprivation therapy (ADT) for […]
MoreNews & Trends - MedTech & Diagnostics

MSAC to assess CGM funding for expanded access in diabetes management
Applications from Abbott Australasia and Australasian Medical & Scientific Limited (AMSL) for public funding of continuous glucose monitoring (CGM) devices […]
More